How will DKSH’s integrated commercial and medical affairs support Lilly in both markets?

Question

Accepted Answer

DKSH to Provide Integrated Commercial and Medical Affairs Support for Lilly in Hong Kong and Macau

DKSH will leverage its extensive expertise in integrated commercial and medical affairs capabilities to ensure continued access to Eli Lilly and Company's medicines for patients in Hong Kong and Macau. This strategic partnership aims to maintain robust patient support programs and uphold high-quality engagement with healthcare professionals, while adhering to stringent global standards for product quality, safety monitoring, and pharmacovigilance. The collaboration builds upon a successful relationship between the two companies in Singapore and Vietnam, extending DKSH's role in market expansion services to these new territories.
Ensuring Continued Access to Medicines

DKSH's primary role will be to guarantee that patients in Hong Kong and Macau continue to receive Lilly's pharmaceutical products without interruption. This includes ensuring that existing patient support programs remain fully operational, providing a crucial safety net for individuals relying on these treatments. The agreement focuses on maintaining the supply chain and accessibility of Lilly's current pharmaceutical portfolio within these markets.
Leveraging Commercial and Medical Expertise

The partnership will see DKSH apply its deep expertise in integrated commercial and medical affairs. This encompasses not only the sales and promotion of Lilly's products but also the vital medical and scientific engagement that healthcare professionals depend on for up-to-date information and support. DKSH's established infrastructure and proven track record in market expansion services are central to this aspect of the collaboration.
Upholding Quality and Safety Standards

A core commitment of DKSH Healthcare in this partnership is the safeguarding of patients. This will be achieved through the rigorous application of global standards for product quality, continuous safety monitoring, and comprehensive pharmacovigilance. These measures are essential to maintaining trust and ensuring the well-being of patients who utilize Lilly's medicines in the region.
Expanding Healthcare Access

This strategic alliance is designed to expand access to reliable healthcare in Hong Kong and Macau. By entrusting DKSH with the distribution and promotion of its pharmaceutical portfolio, Lilly aims to reach more patients in these markets. DKSH, with its in-depth local market knowledge and established marketing and sales capabilities, is positioned to facilitate this expanded reach and bring innovative products to a wider patient population.

Reading history

Hide →

This history is cleared when the page is closed.

How will DKSH’s integrated commercial and medical affairs support Lilly in both markets?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends